SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Solana is a high-performance Layer 1 blockchain designed for mass adoption by providing a fast, secure, and low-cost environment for decentralized applications. It distinguishes itself by scaling globally without the use of complex sharding or multiple layers, instead maintaining a single, unified ledger to avoid liquidity fragmentation. This architecture allows it to process thousands of transactions per second with sub-second finality, often at a cost of less than a penny per transaction.  The network operates on a unique hybrid model that combines Proof of Stake with an innovation called Proof of History, which functions as a decentralized clock to timestamp transactions. This system reduces the need for constant node communication, allowing the Sealevel engine to run non-conflicting smart contracts in parallel across multiple CPU cores. Further efficiency is gained through the Gulf Stream protocol, which reduces confirmation times by forwarding transactions to validators before the current block is finished.  Founded in 2017 by Anatoly Yakovenko, Solana is now supported by the Switzerland-based Solana Foundation and significant institutional investors like Andreessen Horowitz and Polychain Capital. The platform’s native token, SOL, serves as the primary currency for paying transaction fees, participating in network governance, and securing the system through staking.   Solana has also seen significant institutional adoption ranging from spot Solana ETFs to major partnerships including Visa's 2025 launch of USDC settlement on the network and the tokenization of public equity by firms like Galaxy Digital.

Solana

Solana is currently capturing significant community attention as traders closely watch key technical levels, with many discussing its potential to break out of recent consolidation patterns. Investors are actively sharing bullish sentiment and ecosystem updates, while the broader community remains focused on potential institutional adoption and the performance of various memecoins built on the network.

$SWEAT is the beating heart of the Movement Economy—a groundbreaking token that transforms physical activity into real-world value. Minted through movement, $SWEAT rewards your steps with a crypto asset that you can earn, trade, or grow. The team states that their app has increased their users’ physical activity by an average of 20%, creating a healthier society and reducing burdens on global healthcare systems. With over 20 million holders, SWEAT is eliminating barriers and making Web3 accessible to everyone, one step at a time.

Sweat Economy

Sweat Economy is trending as the community debates its long-term potential and utility amidst significant price depreciation, with many users highlighting their commitment to holding or accumulating the asset despite the downtrend. The discussion is heavily mixed with community-driven humor, repetitive sentiment regarding a future turnaround, and ongoing confusion about why the token is surfacing in current search trends.

MNDE is the governance token for Marinade. Marinade helps you to stake Solana without locking in liquidity by turning SOL into mSOL - tokenized version of staked SOL. This way you can both secure the network by staking SOL, and use your mSOL as the ultimate unit in Solana DeFi ecosystem. To provide liquidity, deposit in lending protocols and even buy NFTs.

Marinade

Marinade is seeing increased community interest and speculative volume as traders highlight its role as a leading liquid staking protocol on Solana with a significant gap between its Total Value Locked and market capitalization. The community is actively discussing potential breakout scenarios and long-term upside, often linking the token's performance to broader momentum within the Solana ecosystem.

BlockDAG is a hybrid concept that combines features of both traditional blockchains and DAGs. It retains the benefits of DAGs, such as high scalability and faster transaction processing, while integrating the security and trust of blockchain consensus mechanisms. BlockDAG emerges as a groundbreaking solution, meticulously merging the strengths of both blockchain and DAG architectures. It leverages the robust security and decentralization of blockchains while incorporating the efficient, scalable transaction processing of DAGs. This strategic integration allows blockDAG to handle a significantly higher volume of transactions at faster speeds compared to traditional blockchains. By overcoming the inherent limitations of both technologies, blockDAG paves the way for a future where distributed ledgers can seamlessly scale to meet the ever-growing demands of the cryptocurrency and broader digital landscape.

BlockDAG

BlockDAG is currently facing significant backlash from investors who are struggling with claim issues, inaccessible wallet connections, and concerns that the project is an elaborate, long-running presale scam. The community is actively debating the legitimacy of the project's technology and leadership while many report being unable to access or sell their holdings despite ongoing marketing efforts and new batch releases.

NEAR Protocol is the blockchain for AI. A high-performance, AI-native platform built to power the next generation of decentralized applications and intelligent agents. It provides the infrastructure AI needs to transact, operate, and interact across Web2 and Web3. NEAR combines three core elements: User-Owned AI, which ensures agents act in users’ best interests; Intents and Chain Abstraction, which eliminate blockchain complexity for seamless, goal-driven transactions across chains; and a sharded blockchain architecture that delivers the scalability, speed, and low-cost execution needed for real-world AI and Web3 use. This integrated stack makes NEAR the foundation for building secure, user-owned, AI-native applications at internet scale.

Near

NEAR is generating significant conversation as investors focus on its integration into AI-driven infrastructure and its expanding role in cross-chain liquidity via intents, with many in the community viewing current price action as an accumulation opportunity ahead of potential ecosystem growth.

Ultragenyx Pharmaceutical, Inc. is a biopharmaceutical company, which engages in the identification, acquisition, development, and commercialization of novel products for the treatment of genetic diseases. Its products include Crysvita, Mepsevii, Dojolvi, and Evkeeza. The company was founded by Emil D. Kakkis in April 2010 and is headquartered in Novato, CA.

Ultragenyx Pharmaceutical Inc.

Ultragenyx Pharmaceutical Inc

Ultragenyx Pharmaceutical is currently trending as investors focus on the company's recent Breakthrough Therapy Designation for its Angelman syndrome candidate, GTX-102, and the upcoming pivotal data readouts for its osteogenesis imperfecta asset. Community sentiment remains fixated on the company's pipeline execution and potential for long-term commercial growth, while traders monitor technical setups following recent regulatory milestones.

Roundhill ETF Trust - Roundhill HOOD WeeklyPay ETF

Roundhill Hood WeeklyPay ETF

The Roundhill Hood WeeklyPay ETF is attracting significant investor interest driven by its unique weekly dividend payouts and strong correlation to Robinhood's market performance. Community members are actively debating the fund's income-generation potential relative to its price volatility, with many using the weekly distributions to accumulate additional shares during market dips.

The Ondo Foundation was founded in 2022 as an independently governed and nonprofit Cayman Islands Foundation Company with no beneficial owners. The Ondo Foundation assisted in the launch of the Ondo DAO, which deployed and currently governs Flux Finance, the first lending protocol supporting tokenized securities as collateral.  ONDO token holders are entrusted with shaping the future of the Ondo DAO so that it continues to pursue its mission to democratize access to institutional-grade finance. The Ondo DAO gives ONDO holders specific rights pertaining to Flux Finance, which is currently governed by the Ondo DAO.

Ondo

Ondo is generating significant discussion as a leader in the tokenized real-world assets (RWA) space, with the community closely tracking its institutional partnerships and the potential legislative impact of the Clarity Act. While some investors are bullish on its long-term potential for institutional adoption and tokenization growth, others remain cautious due to concerns regarding token unlocks and recent price volatility.

XDC Network is an enterprise-ready hybrid Blockchain technology company optimized for international trade and finance. The XDC Network is powered by the native coin called XDC. The XDC protocol is architected to support smart contracts, 2000TPS, 2seconds transaction time, KYC to Masternodes (Validator Nodes). The XDC Chain (XinFin Digital Contract) uses XinFin Delegated Proof of Stake (XDPoS), with the intending to create a ‘highly-scalable, secure, permission, and commercial grade’ blockchain network. XinFin mainnet token XDC and also creates an opportunity to utilize the XinFin’s real-world use-cases such as TradeFinex.org, helps small and medium businesses or institutions originate their own financial requirements in a digital, fully structured manner so that they can distribute it to the bank or non-bank funders themselves using a common distribution standard.

XinFin Network

The XinFin Network (XDC) community is heavily focused on long-term accumulation, driven by anticipation of institutional adoption and upcoming regulatory milestones like the Clarity Act. Investors are actively discussing the coin's perceived role in global trade finance and ISO 20022 infrastructure, with many sentiment-focused traders highlighting a cycle of accumulation and patience for a potential breakout.

Unibright &amp; Baseledger - Enterprise Blockchain solutions from Germany  Unibright is a team of blockchain specialists, architects, developers, and consultants with 20+ years of experience in business processes and integration.   Unibright offers Baseledger.net - The blockchain for Baselining (Baseline-protocol.org), Low-code-integration Tools, programmable DeFi with our tokenization platform Freequity and the Universal Business Token (UBT).

Unibright

Unibright is trending as the community actively discusses its enterprise-grade utility, upcoming mainnet developments, and long-term potential compared to broader market trends. Investors are closely monitoring the token's accumulation phase and potential for increased institutional adoption, often drawing comparisons to other high-utility projects in the blockchain space.

statis crypto Watchlist

Bitcoin

Ethereum

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>Bloomberg reported on Friday that Moderna’s hantavirus research is “early-stage and ongoing” and began well before the cruise-ship cluster was identified.&nbsp;</li><li>No hantavirus vaccine is currently approved anywhere in the world, and human clinical trials for Moderna’s candidates have not yet begun.</li><li>Moderna’s vaccine sales have undergone a dramatic post-pandemic decline.</li></ul>Shares of Moderna Inc. (MRNA) closed 12% higher on Friday, clocking its best day in over two months, after the company confirmed it has been pursuing early-stage research into mRNA-based vaccines against hantaviruses.Moderna’s ongoing hantavirus efforts, reported by Bloomberg, coincide with heightened public attention on a rare outbreak linked to the Dutch-flagged MV Hondius. According to the World Health Organization’s Disease Outbreak News report issued earlier this week, seven cases — two laboratory-confirmed hantavirus infections and five suspected — have been identified among passengers and crew.Three people have died, one remains critically ill, and others have reported fever, gastrointestinal symptoms, and rapid progression to pneumonia. Illness onsets occurred between early April and late April 2026 during the ship’s voyage from Ushuaia, Argentina, through Antarctic waters and across the South Atlantic; the vessel is now anchored off Cape Verde.<h2 class="st-heading-2">Moderna’s Hantavirus Efforts</h2>Bloomberg <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.bloomberg.com/news/articles/2026-05-08/moderna-hantavirus-efforts-underway-before-cruise-ship-outbreak">reported</a> on Friday that Moderna’s hantavirus research is “early-stage and ongoing” and began well before the cruise-ship cluster was identified.The company has conducted preclinical work on hantaviruses in collaboration with the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID) and is partnering with the Vaccine Innovation Center at Korea University College of Medicine through its mRNA Access Program to develop a potential immunization, the report said. &nbsp;No hantavirus vaccine is currently approved anywhere in the world, and human clinical trials for Moderna’s candidates have not yet begun. Public-health officials, including the WHO, have described the broader risk to the general population as low, noting that hantaviruses are primarily rodent-borne and human-to-human transmission is uncommon.Moderna’s vaccine sales have undergone a dramatic post-pandemic decline. The company generated a record $19.26 billion in total revenue in 2022, almost entirely from its COVID-19 vaccine Spikevax. Sales then collapsed more than 64% to $6.85 billion in 2023 and fell another 53% to $3.24 billion in 2024 as global demand normalized and advance-purchase agreements ended. Revenue continued to slide in 2025, dropping 40% to $1.94 billion.<h2 class="st-heading-2">How Did MRNA Retail Traders React?</h2>On Stocktwits, retail sentiment around MRNA jumped from ‘bullish’ to ‘extremely bullish’ over the past 24 hours, while message volume increased from ‘high’ to ‘extremely high’ levels.A Stocktwits user expressed optimism for the stock rally upto $250/ share, levels previously touched at the time of the COVID-19 pandemic.<stembedurl>https://www.stocktwits.com/StockQB/message/652807736</stembedurl>Another user voiced optimism for the stock breaching $60/share as early as Monday.<stembedurl>https://www.stocktwits.com/MomentumWins/message/652787271</stembedurl><a href="https://stocktwits.com/symbol/MRNA">MRNA stock</a> has gained 123% over the past 12 monthsRead More: <a href="https://stocktwits.com/news-articles/markets/equity/uber-partner-avride-faces-nhtsa-probe-after-16-robotaxis-crashes-in-texas/cZX2wLERegn">Uber Partner Avride Faces NHTSA Probe After 16 Robotaxi Crashes In Texas</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Moderna headquarters, exterior view, Cambridge, Massachusetts, USA. (Photo by: Plexi Images/GHI/UCG/Universal Images Group via Getty Images)

MRNA Stock Clocks Best Day In Over Two Months On Early-Stage Hantavirus Vaccine Research

Moderna’s ongoing hantavirus vaccine efforts, reported by Bloomberg, coincide with heightened public attention on a rare outbreak linked to the Dutch-flagged MV Hondius.

Equity

Moderna’s ongoing hantavirus vaccine efforts, reported by Bloomberg, coincide with heightened public attention on a rare outbreak linked to the Dutch-flagged MV Hondius.


Noteworthy Friday Option Activity: MRNA, AMD, CCSI

Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Moderna Inc (Symbol: MRNA), where a total of 149,161 contracts have traded so far, representing approximately 14.9 million underlying shares. That amounts to about 243.4...

<ul class="summary-bullets"><li>The plans come on the heels of several complaints from the pharmaceutical industry and sparring with others in the health department over policy, the report added.</li><li>Makary, a former Johns Hopkins surgeon, joined the FDA in November 2024.</li><li>Shares of REPL and QURE jumped as much 17% following the report.</li></ul>President Donald Trump is reportedly considering firing U.S. Food and Drug Administration Commissioner Marty Makary.The Wall Street Journal <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.wsj.com/health/healthcare/trump-planning-to-fire-fda-commissioner-marty-makary-34c072e2">reported</a> on the plans on Friday, citing people familiar with the matter, while noting that other top administration officials believe Makary is struggling to manage his agency. The plans come on the heels of several complaints from the pharmaceutical industry and sparring with others in the health department over policy, the report added.However, the president’s plans are not final and could change, the report said. WSJ noted that Makary, if fired, would become the latest top lieutenant to be fired under Health and Human Services Secretary Robert F. Kennedy Jr., following the departures of CDC Director Susan Monarez last summer and HHS Deputy Secretary Jim O’Neill in February.Makary, a former Johns Hopkins surgeon, joined the FDA in November 2024.<h2 class="st-heading-2">Companies Likely To Benefit from Makary’s Exit</h2>Several biotech and pharmaceutical firms that have publicly clashed with the Makary-led FDA over what they describe as inconsistent, unpredictable, or overly restrictive drug-review processes are viewed as potential beneficiaries of new leadership that could accelerate approvals and restore clearer regulatory guidance.Replimune Group Inc. (<a href="https://stocktwits.com/symbol/REPL">REPL</a>): The FDA rejected the company’s lead melanoma therapy RP1 in a high-profile decision that drew intense industry backlash. Replimune argued the agency treated it unfairly and failed to honor prior commitments made during review meetings; the case became a flashpoint in broader criticism of Makary’s tenure.uniQure N.V. (<a href="https://stocktwits.com/symbol/QURE">QURE</a>): The agency issued a sudden “key shift” in feedback on the company’s Huntington’s disease gene therapy AMT-130, reversing earlier assurances about the sufficiency of its Phase 1/2 data. The FDA strongly recommended a new, randomized, double-blind, sham-surgery-controlled trial.Moderna Inc. (<a href="https://stocktwits.com/symbol/MRNA">MRNA</a>): CEO Stéphane Bancel publicly stated that the FDA under Makary had become “unpredictable” in a way that “threatens U.S. leadership in innovative medicines.” The company experienced surprise setbacks, including an initial refusal to accept a flu vaccine application that was later reversed.Regenxbio Inc. (<a href="https://stocktwits.com/symbol/RGNX">RGNX</a>): The FDA declined to approve the company’s gene therapy for the ultra-rare Hunter syndrome (MPS II) in February 2026, despite prior engagement. Industry observers cited this as part of a pattern of moving goalposts that has frustrated rare-disease developers.Sarepta Therapeutics Inc. (<a href="https://stocktwits.com/symbol/SRPT">SRPT</a>): Sarepta faced repeated conflicts over its Duchenne muscular dystrophy gene therapy Elevidys, including safety and efficacy disputes under Makary’s oversight and the influence of former FDA official Vinay Prasad.Other biotech stocks likely to benefit from under new FDA leadership include Hims &amp; Hers Health (<a href="https://stocktwits.com/symbol/HIMS">HIMS</a>), which faced direct public criticism from Makary over its compounded GLP-1 weight-loss products, and rare-disease gene- and RNA-therapy developers such as Dyne Therapeutics (<a href="https://stocktwits.com/symbol/DYN">DYN</a>), Avidity Biosciences (<a href="https://stocktwits.com/symbol/RNA">RNA</a>), and Lexeo Therapeutics (<a href="https://stocktwits.com/symbol/LXEO">LXEO</a>), all of which have cited inconsistent feedback and delays during Makary’s tenure.Shares of REPL jumped 17% at the time of writing, while QURE rose 15%. MRNA traded 10% higher, while SRPT stock traded 3% lower, and RGNX shares stayed flat.<h2 class="st-heading-2">How Did Retail Traders React?</h2>A Stocktwits user voiced optimism for eventual approval of Replimune’s RP-1 drug, calling the decision to deny it approval a “terrible one.”<stembedurl>https://www.stocktwits.com/History101/message/652782029</stembedurl>Another voiced optimism for “someone better” replacing Makary.<stembedurl>https://www.stocktwits.com/blueb22/message/652773597</stembedurl>While REPL shares fell by about 50% over the past 12 months, QURE rose 124%.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/lucid-uber-partnership-accelerates-after-nuro-lands-key-california-permit-for-gravity-robotaxis/cZX2AwwReg1">LCID-UBER Partnership Accelerates After Nuro Lands Key California Permit for Gravity Robotaxis</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

FDA Commissioner Marty Makary speaks at a news conference on removing synthetic dyes from America's food supply, at the Health and Human Services Headquarters in Washington, DC on April 22, 2025. (Photo by Nathan Posner/Anadolu via Getty Images)

REPL, QURE, MRNA Soar On Reports Trump Will Fire FDA’s Marty Makary 

The Wall Street Journal reported on the plans on Friday, citing people familiar with the matter, while noting that other top administration officials believe Makary is struggling to manage his agency.

What's Going On With Novavax Stock On Friday?

Moderna is researching hantavirus vaccine with U.S. Army while Novavax stock rises due to increased public health threatread more...

Vaccine Trade Returns? Moderna Working On Hantavirus Shot Sends Shares Higher

Vaccine Trade Returns? Moderna Working On Hantavirus Shot Sends Shares Higher Moderna is out with timely news that it is working on early-stage research on vaccines targeting hantaviruses. The news...

MRNA December 2027 Options Begin Trading

Investors in Moderna Inc (Symbol: MRNA) saw new options begin trading today, for the December 2027 expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 588 days until expiration the newly trading contracts...

Moderna Stock Rises On Positive Phase 3 Flu Data: What Investors Need To Know

Moderna Inc (NASDAQ: MRNA) shares are trading higher Friday morning as traders react to peer reviewed Phase 3 flu-vaccine data.read more...

<ul class="summary-bullets"><li>Trump said that the administration will release a full report on a Hantavirus on Friday.</li><li>The outbreak aboard the Dutch-flagged cruise ship Hondius has resulted in three deaths, six confirmed infections and additional suspected cases.</li><li>Moderna drew attention due to its hantavirus vaccine partnership with Korea University.</li></ul>Shares of vaccine makers and biodefense companies rallied overnight on&nbsp;Friday&nbsp;after U.S. President Donald Trump addressed a deadly hantavirus outbreak aboard a cruise ship and promised a full update on the situation.Overnight,&nbsp;<a href="https://stocktwits.com/symbol/EBS">Emergent BioSolutions (EBS)</a> climbed 3%, while&nbsp;<a href="https://stocktwits.com/symbol/INO">Inovio Pharmaceuticals (INO)</a> and&nbsp;<a href="https://stocktwits.com/symbol/NVAX">Novavax (NVAX)</a> each gained 2% and&nbsp;<a href="https://stocktwits.com/symbol/MRNA">Moderna (MRNA)</a> rose 1%.<h2 class="st-heading-2">Trump Promises Full Hantavirus Report</h2>Trump said late Thursday that the administration was closely studying the outbreak from the Dutch-flagged cruise ship Hondius, where three passengers have died and several others became infected. “It’s very much, we hope, under control,” Trump said, adding that a full report will be released on Friday.The outbreak has triggered six confirmed infections and additional suspected cases aboard the vessel, which had 150 passengers onboard during an Atlantic voyage from Argentina toward Europe. Authorities are still investigating how the virus spread on board.Singapore has already isolated two passengers from the ship due to concerns about possible exposure during the trip. The World Health Organization (WHO) also issued an alert on the outbreak, although officials said that the global risk remains low and that hantavirus is less transmissible than COVID-19 or influenza. The virus involved is said to be the Andes strain, one of the few hantavirus variants associated with limited human-to-human transmission.<h2 class="st-heading-2">Moderna Hantavirus Program Back In Focus</h2>Moderna is viewed as one of the U.S. government’s key vaccine platforms for outbreaks. Since 2023, the company has worked with Korea University’s Vaccine Innovation Center on an mRNA-based hantavirus vaccine candidate, with preclinical studies earlier this year showing protection against hantavirus infection in mice.In 2024, Moderna received a $176 million award backed by the Biomedical Advanced Research and Development Authority (BARDA) in 2024 for the development of mRNA-based pandemic influenza vaccines and outbreak preparedness programs. Moderna’s partnership with the Coalition for Epidemic Preparedness Innovations (CEPI) is also in focus, which previously said mRNA could help shorten vaccine-development timelines to as little as 100 days during outbreaks.<h2 class="st-heading-2">Inovio: Direct Hantavirus Play</h2>Inovio, meanwhile, has the clearest hantavirus link among the stocks rallying overnight. The company previously participated in several hantavirus DNA vaccine studies targeting Hantaan, Puumala and Andes hantavirus strains. One National Institute of Allergy and Infectious Diseases-backed study evaluated an Andes virus DNA vaccine to prevent hantavirus pulmonary syndrome, while another U.S. Army-supported study examined mixed hantavirus DNA vaccines.While none of Inovio’s hantavirus vaccine programs produced a commercial product, the outbreak revived speculative interest in companies with prior hantavirus research.<h2 class="st-heading-2">NVAX, EBS In Outbreak Spotlight</h2>Investors frequently rotate into Novavax during virus headlines due to the company’s vaccine-development platform and history of rapidly developing candidates for pathogens such as Ebola, MERS and Zika. The company’s protein-based nanoparticle platform and Matrix-M adjuvant tech can generate vaccine candidates against emerging infectious diseases, already used in marketed COVID-19 and malaria vaccines.&nbsp;Emergent BioSolutions, on the other hand, is often viewed as one of the U.S. government’s primary biodefense and medical-countermeasure contractors during public-health emergencies. The company has existing relationships with BARDA and makes products based on Anthrax, Ebola, smallpox, mpox and viral hemorrhagic fevers. Emergent previously received BARDA task orders for viral hemorrhagic fever therapeutics and has also participated in manufacturing efforts during outbreaks, including Ebola and Zika.<h2 class="st-heading-2">How Do Retail Traders Feel About INO, MRNA, NVAX, EBS?</h2>On Stocktwits, retail sentiment for INO and NVAX was ‘extremely bullish’ amid ‘extremely high’ message volume, while MRNA saw ‘bullish’ sentiment with ‘high’ message volume. EBS also recorded ‘extremely bullish’ sentiment, though message volume remained ‘normal.’&nbsp;Over the past year, MRNA has surged 102%, followed by EBS up 93% and NVAX higher by 55%, while INO has declined 22%.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com.Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/sls-stock-deutsche-bank-stake-boost-ahead-of-earnings/cZX2EhiReXG">SLS Stock Heads For Weekly Win: Deutsche Bank’s Stake Boost Draws Attention Ahead Of Q1 Earnings&nbsp;</a>

Trump holds a press conference announcing U.S. Vice President Mike Pence to lead the effort combating the spread of the coronavirus on February 26, 2020. (Photo by Yasin Ozturk/Anadolu Agency via Getty Images)

INO, MRNA, NVAX, EBS Jump Overnight: Trump Promises Full Hantavirus Report As Deadly Outbreak Sparks Vaccine Rally

Inovio is the most direct hantavirus play based on earlier DNA vaccine studies targeting Andes, Hantaan, and Puumala strains.

Biotech’s Next Wave May Already be in Motion

The biotech and pharma sector is entering one of its most pivotal periods in years, where insider conviction, late-stage clinical wins, and platform technologies are converging to reshape both valuations and patient outcomes. From aggressive insider buying ahead of critical data to blockbuster Phase 3 readouts redefining entire therapeutic categories, the market is signaling that the next cycle of winners may already be taking shape. $NTHI, $ERNA, $LLY, $NVO, $REGN, $MRNA

<ul class="summary-bullets"><li>Novavax posted Q1 revenue of $139.5 million, above analysts’ estimate of $78.3 million, helped by licensing agreements.</li><li>The drugmaker also said that patients who received Nuvaxovid were “twice as likely” to say they would choose the same vaccine again the following year.</li><li>The company maintained its 2026 adjusted revenue outlook of $230 million to $270 million.</li></ul>Shares of Novavax (NVAX) are headed for a breakout week as the vaccine maker reported solid first quarter (Q1) results and spotlighted data showing that patients were “twice as likely” to choose its COVID shot again over a rival vaccine from Moderna<a href="https://stocktwits.com/symbol/NVAX">NVAX stock</a> jumped 16% on Wednesday to end at $9.36. Shares are eyeing their best week in about nine months.<h2 class="st-heading-2">Novavax Touts Lower Side Effects Vs Moderna</h2>Novavax reported Q1 revenue of $139.5 million, beating analysts’ estimate of $78.3 million. The results were boosted by upfront and milestone payments from licensing and vaccine supply partnerships as the company shifts away from relying primarily on direct COVID vaccine sales.The rally also came as investors focused on fresh data comparing Novavax’s protein-based COVID vaccine, Nuvaxovid, against Moderna’s mNEXSPIKE shot.During the earnings call, Novavax highlighted findings from Sanofi’s head-to-head Phase IV Compare study, which tested Nuvaxovid directly against Moderna’s vaccine. The Maryland-based company said Nuvaxovid showed “statistically fewer side effects compared to mNEXSPIKE, across all prespecified endpoints.”Novavax added that people who received Nuvaxovid were “twice as likely as mNEXSPIKE recipients to say they would definitely choose the same vaccine type again the following year.” The company also pointed to real-world data from the Shield study conducted with the University of Utah, saying that participants who received Nuvaxovid reported fewer side effects and “half as many hours of lost work” compared with recipients of mRNA vaccines.The findings are notable since Novavax’s turnaround depends on its protein-based vaccine as a differentiated alternative in the crowded COVID and future combination flu-COVID market. Novavax believes the combined COVID-flu vaccine market could eventually represent a $10 billion to $12 billion opportunity.<h2 class="st-heading-2">Pfizer, Sanofi Deals Fuel NVAX Optimism</h2>While demand for standalone COVID vaccines has weakened globally, Novavax is leaning on licensing agreements and partnerships to drive growth. The company received a $30 million upfront payment during the quarter from its Matrix-M adjuvant agreement with pfizer. Matrix-M is Novavax’s in-house ingredient that helps the body build a stronger immune response after vaccination.&nbsp;“Despite whatever is happening in the macro environment, there seems to be a very strong interest,” CEO John C. Jacobs said during the conference call. The company said that its partners are currently exploring over 30 infectious disease and cancer indications using Matrix-M.&nbsp;“Our partnerships with Sanofi and Pfizer have the potential on their own, to generate billions in revenue from milestone and royalty opportunities,” Jacobs said. Sanofi is developing combination flu-COVID vaccines using Nuvaxovid under a deal worth at least $1.2 billion.<h2 class="st-heading-2">NVAX Reaffirms 2026 Revenue Outlook</h2>Novavax maintained its 2026 adjusted revenue forecast in the range of $230 million and $270 million, excluding royalties and sales from the Sanofi agreement. The company also reiterated that it expects its existing cash position and partner reimbursements to fund operations into 2028 even without additional milestones or royalty revenue. Novavax posted a Q1 net loss of just $9 million and continues targeting non-GAAP profitability by 2028.&nbsp;After the earnings report and updated vaccine data, TD Cowen raised its price target on Novavax to $9 from $8, still implying a 4% downside from current levels, while maintaining a ‘Hold’ rating. The brokerage cited the Sanofi-led head-to-head study and growing evidence that Nuvaxovid may offer a differentiated tolerability profile compared with other mRNA vaccines.<h2 class="st-heading-2">How Do Retail Traders Feel About NVAX?</h2>On Stocktwits, retail sentiment for NVAX was ‘extremely bullish’ amid over a 430% surge in 24-hour message volumes.<figure class="image"><img src="https://news.stocktwits-cdn.com/nvax_ss_png_50a26f969e.webp" alt="nvax ss.png" width="968" height="142"><figcaption>NVAX sentiment and message volume as of May 7 | Source: Stocktwits</figcaption></figure>One user&nbsp;<a href="https://stocktwits.com/topstockalerts/message/652530627">said</a>, “not chasing but definitely watching this closely”<stembedurl>https://stocktwits.com/topstockalerts/message/652530627</stembedurl>Another user&nbsp;<a href="https://stocktwits.com/Bodu/message/652514332">said</a>, “Lean organization, massive $100 billion market. No rush. Im not expecting to be rich tomorrow but I do expect it to happen in a year”<stembedurl>https://stocktwits.com/Bodu/message/652514332</stembedurl>NVAX stock has risen 54% over the past year.For updates and corrections, email newsroom[at]stocktwits[dot]com.Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/nio-stock-es9-launch-drowns-out-fresh-ubs-sell-down/cZXbcphRefg">Nio Stock Jumps In HK: ES9 Launch Buzz Drowns Out Fresh UBS Sell-Down&nbsp;</a>

 Ampoules containing the new Corona vaccine Nuvaxovid from the manufacturer Novavax sit on a table at a vaccination center. Photo: Matthias Bein/dpa (Photo by Matthias Bein/picture alliance via Getty Images)

NVAX Stock Eyes Breakout Week: Novavax Claims Patients Were ‘Twice As Likely’ To Pick Its COVID Shot Over Moderna Again 

The company spotlighted new data showing that its COVID vaccine, Nuvaxovid, produced “statistically fewer side effects” than Moderna’s mNEXSPIKE vaccine.

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The firm's product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. It operates through the following geographical segments: United States, Europe, and Rest of World. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rossi, and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Moderna Inc

Up > 1%

Flat +/- 1%

Down > 1%

Where does the $SPY finish next week vs. Friday’s close?

Stocktwits

Stocktwits Polls

Speculation surrounding mRNA-based vaccine development is fueling intense market volatility and contagion fears.

Positive NEJM phase 3 flu vaccine data is driving institutional buying and expanding the company's long-term commercial platform.

High short interest paired with new pandemic fears has traders betting on a parabolic short-covering rally.

Current Price	$54.35
Prev Close	$48.54
Open	$49.00
Dividend Yield	0.00%
50-Day Moving Average	$51.60
Beta	1.35
Avg. Volume	5.54M
PE Ratio	-6.67

52-Week High	$59.55
52-Week Low	$22.28
Market Capitalization	$21.57B
EPS (Annual)	-$7.25
Price to Book	2.91
Revenue Per Employee	$413,617.02

MRNA
Moderna Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest MRNA News

MRNAModerna Inc